Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Talaris takes home $100m series A
Talaris, previously known as Regenerex and based on research at University of Louisville, will use the funding to advance its cell therapy into later-stage clinical development.
Sila Nano recharges with $170m
Battery materials developer Sila Nanotechnologies, co-founded by Georgia Tech professor Gleb Yushin, is preparing for commercialisation, after Daimler led a series E round.
AskBio pops $235m question
Asklepios BioPharmaceutical, based on work by UNC Chapel Hill professors Jude Samulski and Xiao Xiao, has secured $235m in funding co-led by TPG Capital and Vida Ventures.
Fusion gets reaction in $105m series B
Varian led a round for the targeted cancer drug developer that included existing investors such as Facit and Johnson & Johnson.
SambaNova snags $150m
Stanford-founded AI application platform developer SambaNova has raised $150m in a series B round led by Intel Capital that also featured existing investor GV.
Beam hits series B with $135m
GV participated as a new investor, as Harvard's genetic medicine developer Beam Therapeutics completed a round that followed $87m in series A funding last year.
Maze finds its way to $191m
GV and Alexandria have taken part in a $191m round to launch Maze Therapeutics with scientific co-founders from multiple universities such as Harvard and Stanford.
Passage Bio follows $116m series A trajectory
Passage Bio will develop therapies for diseases affecting the central nervous system based on research by James Wilson at Penn, after raising almost $116m in a series A round.

Other News

Haihe Biopharma greets CAS to raise cash
Chinese Academy of Sciences invested in a round that will be used to take Haihe's anti-tumour therapies further down the clinical path.
ClearMotion rides investor interest to raise $115m
Microsoft, Bridgestone and Qualcomm all contributed to a series D round for MIT spinout ClearMotion, which emerged from stealth earlier last year with $130m in funding.
Tuspark identifies 4Paradigm in $145m series C
4Paradigm has now won backing from Tsinghua University Science Park for its technology, which helps clients build AI apps for purposes including financial services.
Poynt takes $100m series C payment
Backed by Stanford-Start X Fund and a trio of corporates, Poynt has now received more than $128m in total for its payment processing terminal and software business.
Amgen inserts $66m into Oxford Nanopore
Oxford Nanopore has secured $66m from Amgen, after the latter’s subsidiary Decode Genetics used the spinout’s technology to sequence hundreds of human genomes.
Atreca carries on funding streak

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Immunocore smashes European biotech records
Immunotherapy firm Immunocore, which started life at Oxford University, raises the largest biotech round in European history.
test reg